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The lack of defined correlates of protection hampers development of vaccines against
tuberculosis (TB). In vitro mycobacterial outgrowth assays are thought to better capture the
complexity of the human host/Mycobacterium tuberculosis (Mtb) interaction. Here, we used
a mycobacterial growth inhibition assay (MGIA) based on peripheral blood mononuclear
cells to investigate the capacity to control outgrowth of bacille Calmette-Guérin (BCG).
Interestingly, strong control of BCG outgrowth was observed almost exclusively in
individuals with recent exposure to Mtb, but not in (long-term) latent TB infection, and only
modestly in BCG vaccinees. Mechanistically, control of mycobacterial outgrowth strongly
correlated with the presence of a CD14dim monocyte population, but also required the
presence of T cells. The nonclassical monocytes produced CXCL10, and CXCR3 receptor
blockade inhibited the capacity to control BCG outgrowth. Expression of CXCR3 splice
variants was altered in recently Mtb-exposed individuals. Cytokines previously associated
with trained immunity were detected in MGIA supernatants, and CXCL9, CXCL10, and
CXCL11 represent new markers of trained immunity. These data indicate that CXCR3
ligands are associated with trained immunity and are critical factors in controlling
mycobacterial outgrowth. In conclusion, control of mycobacterial outgrowth early after
exposure to Mtb is the result of trained immunity mediated by a CXCL10-producing
nonclassical CD14dim monocyte subset.
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Introduction
Tuberculosis (TB) remains a major threat to human global health, 
with an estimated one-fourth of the world population latently 
infected and lifetime reactivation rates between 3% and 10% 
(1). Annually approximately 2 million people die of TB disease, 
including those suffering from concomitant HIV infection (2). The 
WHO aims to reduce the burden of TB disease by 2035 (2), and 
mathematical modeling predicts that successful novel vaccination 
strategies would be essential to reach that goal (3, 4). However, 
clinical evaluation of new TB vaccines is hampered by the long 
latency period following infection with Mycobacterium tuberculosis 
(Mtb) and the low proportion of infected individuals that eventu-
ally develop TB disease, thus necessitating large and long-term 
follow-up studies to determine efficacy against clinical endpoints 
such as prevention of (or progression to) disease. Production of 
IFN-γ in response to Mtb antigen stimulation has been the gold 
standard of anti-Mtb immunity. Although IFN-γ is required, it 
is not sufficient for protection against TB disease development 
(5, 6), and preclinical studies even show that high IFN-γ can be 
detrimental such that “more can be worse” (7). Despite intense 
research efforts, correlates and mechanisms of (vaccine-induced) 
protection in TB have remained elusive, hampering rationalized 
correlate-based down-selection of the expanding list of novel vac-
cine candidates.
Mycobacterial growth inhibition assays (MGIAs) measure the 
capacity of whole blood (8) or isolated peripheral blood mono-
nuclear cells (PBMCs) to inhibit the outgrowth of mycobacteria, 
including bacillus Calmette-Guérin (BCG) (9–13) and Mtb (14). 
There is a long-standing interest in measuring and understand-
ing the capacity of the immune system to control mycobacterial 
growth. Several biological assays to quantitate mycobacterial 
growth have been used over the years, including mycobacteria 
expressing a reporter (luciferase) (9, 15, 16). In addition, Hoft and 
colleagues used primary as well as secondary lymphocyte inhibi-
tion assays followed by CFU counting (17–19). Wallis et al. adapt-
ed mycobacterial cultures in the BACTEC MGIT system (Becton, 
Dickinson and Co.) to investigate not only drug sensitivity but also 
effector immunity (20, 21). Over time, several aspects of these 
different approaches have been integrated into the MGIA assay 
that is currently used by several groups and includes infection of 
PBMCs with mycobacteria for several days, followed by incubation 
in BACTEC MGIT tubes to assess mycobacterial growth capacity 
(9, 10, 12, 22). Development and optimization of the MGIA assay 
as it is currently used have been recently reviewed at length (10, 
23). MGIA assays have been used already for cells of human (9, 
12, 24–26), nonhuman primate (26), and mouse (11, 13, 14) origin.
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tive CFU counts over 9 individual experiments were highly repro-
ducible (Supplemental Figure 1B), as were the time-to-positivity 
(TTP) readouts from the BACTEC over the same dilutions (Sup-
plemental Figure 1C).
BCG vaccination has been widely used for almost a century, 
but the protection it affords in human populations has been high-
ly variable, likely depending on population geography and previ-
ous exposure to environmental factors. We analyzed a cohort of 
young, mycobacterially naive (purified protein derivative–negative 
[PPD-negative]) Dutch adults before and at several time points 
after BCG vaccination (30). We observed considerable variation in 
mycobacterial growth inhibition between these individuals during 
follow-up time points, and there appeared no single common time 
point at which mycobacterial outgrowth across all participants was 
significantly improved following vaccination (Figure 1A). Howev-
er, we noticed that several individuals had considerable growth 
control at 4 weeks after vaccination (left panel), whereas others 
controlled BCG outgrowth only at 8 (middle panel) or 12 weeks 
(right panel) after vaccination, suggesting different kinetics in the 
response (30). Therefore, we compared the prevaccination MGIA 
result with the results at the peak response for each individual (4, 8, 
or 12 weeks after vaccination), and then observed a significant inhi-
bition of mycobacterial outgrowth (Figure 1B). It was remarkable 
that samples with significant control at 1 time point (e.g., week 4 or 
8) had lost that capacity at the next sampling time point, which was 
only 4 weeks later (Figure 1A), suggesting a limited role of imprint-
ed adaptive immunity. Thus, although there was significant BCG 
growth reduction following BCG vaccination, the magnitude of 
BCG growth control was rather modest and transient.
LTBI and TB infection: recent exposure associated with strong 
bacterial growth control. Given the observation that LTBI protects 
significantly against TB (see above) (27), we decided to assess the 
capacity of PBMCs from several Mtb-infected cohorts to control 
BCG outgrowth. We also included TB patients with active disease as 
well as a control group composed of healthy, mycobacterially naive 
Dutch donors. Altogether, patients with active TB did not control 
BCG outgrowth in the MGIA assay (Figure 1C), although we could 
discriminate 2 subgroups with a different functional response. We 
have critically analyzed the available clinical parameters of these 
groups, including disease localization (pulmonary vs. extrapulmo-
nary localization), ethnicity, and suggestion of long-term existing 
disease, but we were not able to identify any parameter associated 
with good or poor inhibition of BCG outgrowth.
As only a proportion of latently infected individuals progress-
es to disease, the capacity to inhibit mycobacterial outgrowth 
may be expected to characterize the majority of latently infect-
ed donors, especially those who have been latently infected for a 
long period without developing disease. Contrary to our expecta-
tion, however, a cohort of latently infected individuals from the 
Netherlands (31) as well as a group of elderly Norwegian indi-
viduals (32, 33) known to be latently infected with Mtb for about 
3 decades (based on tuberculin skin test conversion and IFN-γ 
release assay  positivity) failed to inhibit BCG outgrowth in the 
MGIA assay (Figure 1, D and E). The LTBI cohort from the Neth-
erlands was composed of individuals with a positive tuberculin 
skin test (TST), and most individuals also had a positive Quan-
tiFERON-TB Gold (QFN; QIAGEN) response. For most individ-
Although these functional assays may reflect the capacity 
of individuals to control mycobacterial outgrowth, the underly-
ing mechanism remains unknown. BCG-vaccinated mice have 
reduced Mtb loads following infection compared with nonvacci-
nated animals, and this is paralleled by their splenocytes’ capacity 
to reduce mycobacterial outgrowth in MGIA (11, 13), supporting 
the assay’s biological validity. BCG vaccination has mostly been 
used in such studies, because BCG affords at least partial protec-
tion against severe manifestations of TB disease, and efficiently 
induces IFN-γ–producing T cells (9, 11, 13, 14, 25, 26). Although 
many researchers have attempted to identify the cellular sub-
set(s) responsible for mycobacterial growth control, their identity 
remains inconclusive, and to some extent even elusive. Associa-
tions have been found with monocyte/lymphocyte ratios (24), 
multifunctional CD4+ T cells (25), and iron metabolism (26). 
Increased iron concentrations, in particular in whole blood–based 
MGIA assays but also in PBMC assays, significantly promoted the 
in vitro growth capacity of mycobacteria, such that some caution 
should be applied to interpreting data from whole blood–based 
MGIA assays (26).
Mtb infection results in progression to disease in only a small 
proportion (3%–10%) of those infected, while the majority of indi-
viduals apparently is able to control mycobacterial outgrowth (2). 
Recent meta-analyses have shown that latent infection with Mtb 
(LTBI) results in a striking 79% protection against reinfection 
with Mtb, suggesting strong protective host responses induced by 
Mtb infection (27). Although protection against infection is often 
thought to be associated with the induction of adaptive immune 
responses, a recent concept suggests that epigenetic modifica-
tion of monocytes may also contribute to protection (28). This 
phenomenon has been termed “trained immunity,” and hall-
mark cytokines produced by these trained monocytes are IL-1β, 
IL-6, and TNF-α (28, 29). To explore this biological process and 
to uncover new biology and corresponding correlates of mycobac-
terial inhibition, we decided to investigate the capacity of PBMCs 
from cohorts of BCG vaccinees, as well as individuals with LTBI, 
patients with active TB, and people from contact investigations 
following recent TB exposure. PBMC samples with unexpectedly 
strong control of mycobacterial outgrowth were observed. These 
were subsequently used to unravel the mechanism of mycobacte-
rial growth control.
Results
MGIA in BCG cohorts: limited and transient bacterial growth con-
trol. Mycobacterial growth inhibition assays (MGIAs) provide an 
important and hypothesis-free readout of functional (bacterial) 
growth inhibition by the human immune system. However, in order 
to apply such functional assays in further research and eventually 
for rationalized TB vaccine selection, it is essential to optimize the 
assay toward high reproducibility and robustness. Using a frozen 
stock of BCG and an extensive thawing procedure, we were able 
to obtain solidly reproducible standard curves across experiments 
(Supplemental Figure 1A; supplemental material available online 
with this article; https://doi.org/10.1172/JCI97508DS1). Serial 
dilutions were generated as standard curves for each independent 
experiment, and each standard was plated in a 10-fold dilution 
series (Supplemental Figure 1D) to obtain CFU counts. Cumula-
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Next, in order to study this directly, we included samples 
from 3 fully independent TB contact investigations in the Nether-
lands: these involved a professional soccer club (34), a supermar-
ket outbreak (35–37), and a group of immigrants with recent (re)
exposure to Mtb (38, 39). Interestingly, all 3 cohorts considerably 
uals in our LTBI cohort it is hard to estimate the time since Mtb 
infection, and since our BCG vaccination studies also revealed 
a temporal inhibition in BCG growth following vaccination, we 
hypothesized that mycobacterial growth control might be stron-
gest recently after mycobacterial (TB) exposure.
Figure 1. Mycobacterial growth control is associated with recent TB exposure. PBMCs were infected with live BCG, rotated 4 days, and incubated in MGIT 
tubes in the BACTEC machine. Horizontal lines indicate medians. “Δ median” indicates the difference in medians between groups. (A) PBMCs collected before 
BCG vaccination, 4, 8, and 12 weeks after vaccination, and 1 year after vaccination. Left plot indicates donors with the strongest reduction in BCG growth at 
week 4 (n = 8), middle plot at week 8 (n = 2), and right plot at week 12 (n = 6). (B) For each individual from A, the time point with maximal MGIA control was 
compared with the prevaccination sample using the Wilcoxon paired-rank test. (C–G) All groups in C–G were compared with a common group of 30 controls 
— 16 individuals prior to BCG vaccination and 14 blood bank donors — using the Kruskal-Wallis test. (C) Patients with active TB disease (n = 19). (D) Individuals 
with latent TB infection (LTBI; n = 22). (E) Individuals with long-term LTBI (lt-LTBI; n = 20). An age-matched control group (lt-LTBI ctr; n = 10) was included. 
(F) Three independent cohorts of recently TB-exposed individuals collected during contact investigations: 35 at a soccer club, 11 in a supermarket, and 39 
immigrants with recent exposure to active TB. (G) Combined analysis of all groups tested: BCG (n = 16 at peak response); recently exposed (F: n = 85); LTBI 
(from D and E: n = 42); active TB (from C). Data were compared using the Kruskal-Wallis test. Dashed lines indicate the lower limit of the CI of the median of 
the controls, and the 1 log reduction compared with this median. Samples above the CI of median lacked control of mycobacterial outgrowth and samples with 
more than 1 log reduction had good control.
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uals but also in BCG-vaccinated individuals as well as a subset 
of TB patients. Taken together, most individuals in the recently 
exposed group had intermediate or good control, whereas only a 
small proportion of individuals in the other groups showed such 
BCG growth inhibition.
The capacity to control BCG outgrowth was compared with 
clinical measures of Mtb infection status, the TST and QFN, both 
measures of induced adaptive immunity. Surprisingly, PPD-in-
duced TST induration correlated inversely with the capacity to 
control BCG outgrowth in the MGIA (Supplemental Figure 2A). 
However, this was mostly due to the large proportion of individ-
uals that had negative skin test results and relatively good MGIA 
controlled BCG outgrowth in the MGIA assay (Figure 1F), with a 
change of about 1 log compared to the median of the control pop-
ulation. To the best of our knowledge, this is the highest level of 
mycobacterial control reported for human PBMCs so far. Com-
bination of all independent cohorts, previously shown above, 
according to infectious status, showed that recently exposed indi-
viduals inhibited BCG outgrowth best (Figure 1G). Good control, 
defined as more than 1 log reduction compared with the control 
population, was almost only observed in donors who were recent-
ly exposed. Intermediate control (between the lower confidence 
interval [CI] value and 1 log reduction of the median of the con-
trols) was observed most frequently in recently exposed individ-
Figure 2. Mycobacterial growth control is not associated with multifunctional T cells. PBMCs were infected with live BCG and rotated for 4 days, and samples 
were incubated in MGIT tubes in the BACTEC machine. Antibody marker staining for FACS analysis was performed after 16 hours of negative control or live BCG 
stimulation. Data from all independent cohorts were combined. Associations were determined using linear regression modeling (n = 144). (A) The percentage 
of CD19+ B cells was positively correlated with mycobacterial growth control. (B) The percentage of CD3+ T cells was correlated inversely with mycobacterial 
growth control. (C) The percentage of CD4+ T cells producing IFN-γ, IL-2, and TNF-α (multifunctional T cells) following 16 hours of BCG stimulation over the 
different clinical groups. Groups were compared using the Kruskal-Wallis test. Higher numbers were observed in LTBI and TB groups. Controls, n = 38; BCG,  
n = 16; exposed, n = 50; LTBI, n = 35; TB, n = 19. (D) The percentage of CD4+ T cells producing IFN-γ, IL-2, and TNF-α did not correlate with the capacity to control 
mycobacterial outgrowth (n = 144). (E) The percentage of CD4+ central memory (CM; CD45RA–CCR7+) T cells correlated with the capacity to control mycobacte-
rial outgrowth (n = 148). (F) Summary of correlation data between CD4+ or CD8+ T cell subsets based on the expression of CD45RA and CCR7 and the capacity 
to control mycobacterial outgrowth. Positive correlations indicate that increased expression of the population is associated with better growth control; inverse 
correlations indicate that increase in the population is associated with decreased growth control. N, naïve; EM, effector memory; E, effector.
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inversely related to control in the MGIA (Figure 2B). Since it was 
previously reported that multifunctional T cells were associated 
with MGIA results (25), we also enumerated multifunctional 
T cells in our samples (gating strategies are given in Supplemen-
tal Figure 7, A and B). However, the frequency of CD4+ T cells 
producing IFN-γ, TNF-α, and IL-2 was very low in our cohorts, 
although significant differences were identified (Figure 2C). The 
same was true for CD8+ multifunctional T cells (Supplemental 
Figure 3A). There was no correlation between the frequency of 
CD4+ multifunctional T cells and the MGIA results (Figure 2D), 
nor was there for CD8+ multifunctional T cells (Supplemental Fig-
ure 3B). In addition, none of the single-cytokine-producing CD4+ 
or CD8+ T cells (Supplemental Figure 3, C and D) was associated 
with MGIA activity (Supplemental Figure 3, E and F).
control. If these individuals were excluded from the analysis, the 
negative correlation was lost. There also was no positive correla-
tion between the absolute QFN result and BCG growth control 
(Supplemental Figure 2B). However, a considerably sized group of 
individuals lacked cellular immunity toward Mtb antigens while 
having good control of BCG outgrowth in the MGIA.
Immune correlate analysis: CD14dim monocytes correlate with 
MGIA control. To decipher the mechanism of mycobacterial 
growth control mediated mostly by the samples from recently 
exposed individuals, we analyzed associations with several 
immune cell subsets and functions. The percentage of CD19+ 
B cells correlated with the capacity to control BCG in the MGIA, 
as higher proportions of B cells were associated with decreased 
CFU (Figure 2A). In contrast, the percentage of CD3+ T cells was 
Figure 3. Capacity to control mycobacterial growth is associated with a CD14dim myeloid population. PBMCs were infected with live BCG and rotated for 4 
days, and samples were incubated in MGIT tubes in the BACTEC machine. Antibody marker staining for FACS analysis was performed after 16 hours of neg-
ative control stimulation. Associations were determined using linear regression modeling (n = 144). (A) The percentage of CD14+ monocytes was positively 
correlated with mycobacterial growth control. (B) The monocyte/lymphocyte (ML) ratio (% CD14/CD3) correlated with mycobacterial growth control. (C) 
Representative dot plots of monocyte profiles in individuals with good mycobacterial growth control (more than 1 log reduction of BCG outgrowth com-
pared with the median of the control population), intermediate control (between 1 log reduction and lower limit of the CI of median of control population; 
see Figure 1G), or no control (above lower limit of the CI of median of control population). There was a strong CD14dim population in the individuals with 
mycobacterial growth control. (D) Recently exposed individuals had the highest proportion of CD14dim cells; open symbols indicate donors with good control 
in the MGIA. Controls, n = 37; BCG, n = 16; exposed, n = 50; LTBI, n = 34; TB, n = 19. (E) The percentage of CD14bright monocytes was not correlated with myco-
bacterial growth control (n = 144). (F) The percentage of CD14dim monocytes was positively correlated with mycobacterial growth control (n = 144).
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In contrast, however, analysis of different memory T cell pop-
ulations revealed a strong association (P < 0.0001) of CD4+ cen-
tral memory T cells with the capacity to control BCG outgrowth 
(Figure 2E; gating strategies are given in Supplemental Figure 
7C). Both CD4+ and CD8+ effector cell frequencies were inversely 
related with MGIA control (Figure 2F and all data in Supplemental 
Figure 4, A and B).
In addition to cells involved in adaptive immunity, we also 
assessed monocytes, being the primary targets of BCG infection. 
The percentage of CD14+ monocytes correlated significantly with 
the capacity to control BCG outgrowth in the MGIA (P = 0.0006) 
(Figure 3A). An even stronger correlation with MGIA activity 
was seen when we expressed monocyte/lymphocyte (ML) ratios, 
which were obtained by division of the percentage of CD14+ cells 
by that of CD3+ cells (P < 0.0001) (Figure 3B). When analyzing 
these CD14 data we noticed that particular samples had a very 
abundant CD14dim population (Figure 3C). Therefore, we ana-
lyzed CD14dim and CD14bright populations separately and found 
that the CD14dim population was most abundantly present in indi-
viduals recently exposed to Mtb (Figure 3D). Interestingly, not 
the frequency of the CD14bright (Figure 3E) but that of CD14dim cells 
(P < 0.0001) (Figure 3F) correlated with the capacity to control 
BCG outgrowth in the MGIA.
Thus we have identified a CD14dim monocyte subset that is 
increased upon recent exposure to Mtb, and correlates with the 
capacity to control BCG outgrowth.
Nonclassical monocytes are associated with MGIA control and 
production of CXCL10. CD14dim monocytes are nonclassical 
monocytes that are further characterized by the expression of 
particular chemokine receptors. Indeed, CD14bright cells expressed 
increased levels of CD163, CCR2, and CX3CR1, but CD14dim cells 
expressed higher levels of CCR5, consistent with a nonclassical 
monocyte subset phenotype (Figure 4A). Further work revealed 
that a large proportion of the CD14dim population produced the 
chemokine CXCL10. In contrast, TNF-α was generally produced 
by CD14bright cells (Figure 4B). Most importantly, the proportion 
of CXCL10-producing monocytes was associated with the capac-
ity to control BCG outgrowth (Figure 4C). The capacity to con-
trol BCG outgrowth was associated not with CXCL10-producing 
CD14bright cells (Figure 4D), but with CXCL10-producing CD14dim 
cells (Figure 4E). The proportion of total CD14+, CD14bright, or 
CD14dim cells producing TNF-α did not correlate with the capacity 
to reduce BCG outgrowth (Supplemental Figure 5, A–C).
Interestingly, follow-up of individuals exposed in the super-
market outbreak allowed longitudinal assessment of the capac-
ity to control BCG outgrowth. The capacity to control BCG out-
growth persisted during the first 2 years after exposure, and time 
points with the strongest reduction in BCG outgrowth contained 
the highest frequency of CD14dim monocytes (Figure 4F). Longi-
tudinal follow-up was available only for the supermarket study 
and for the Dutch cohort of LTBI individuals. In the supermar-
ket contact investigation with recent Mtb exposure, control in the 
MGIA was maintained throughout the 2-year follow-up. Although 
strong control was achieved, this did not result in sterile eradica-
tion of the BCG in the MGIA assay (Supplemental Figure 6A). In 
the more remote LTBI cohort, however, no control was observed 
during follow-up (Supplemental Figure 6B). In agreement with 
the above results, the supermarket group had increased ML 
ratios, increased frequencies of CD14dim cells, and increased fre-
quencies of CXCL10-producing CD14dim cells, whereas none of 
these were observed during follow-up of the LTBI cohort (Supple-
mental Figure 6, C–H).
Thus, our functional and immunological analyses identify 
strong correlations between the capacity to control BCG out-
growth in the MGIA and the presence of a nonclassical mono-
cyte subset characterized by decreased expression of CD14, that 
produced CXCL10.
Mechanistic involvement of CXCL10/CXCR3 signaling requires 
the presence of T cells. Since the frequency of CXCL10-producing 
CD14dim monocytes was strongly associated with MGIA control, 
we next investigated the concentration of CXCL10 and its close-
ly related family member CXCL9 in the supernatants of the 4-day 
MGIA assay. CXCL9 and CXCL10 were present at the highest 
levels in donors recently exposed to TB, although concentrations 
varied between individuals (Figure 4G). The third CXCR3-binding 
family member, CXCL11, could not be detected in the same MGIA 
supernatants. CXCL9 and CXCL10 bind to CXCR3 as their cognate 
receptor. NBI-74330, a chemical CXCR3 receptor antagonist, was 
added to the MGIA assay during the 4 days of incubation. Controls 
with the CXCR3 antagonist and BCG bacteria only, in the absence 
of PBMCs, revealed no difference in BCG outgrowth kinetics, 
excluding direct effects of the inhibitor on bacterial growth. Addi-
tion of the inhibitor to PBMCs from samples that controlled BCG 
outgrowth abrogated the reduction in BCG CFU, indicating that 
the CXCR3/CXCL10 axis is functionally involved in controlling 
BCG outgrowth (Figure 5A; raw data given in Supplemental Table 
1). Interestingly, PBMC samples that lacked BCG outgrowth con-
trol showed increased capacity to control BCG outgrowth upon 
addition of the CXCR3 antagonist NBI-74330, to a small but signifi-
cant extent (Figure 5B). Analysis of the supernatants of these cocul-
Figure 4. Nonclassical monocytes produce CXCL10 and are involved in 
mycobacterial growth control. PBMCs were infected with live BCG and 
rotated for 4 days, and samples were incubated in MGIT tubes in the BAC-
TEC machine. Antibody marker staining for FACS analysis was performed 
after 16 hours in the absence of specific stimulation in the presence of 
BFA. Associations were determined using linear regression modeling, and 
P less than 0.05 was considered significant. (A) Concatenated gate of 
CD14dim and CD14bright cells for monocyte subset markers revealed a nonclas-
sical monocyte expression pattern of the CD14dim population consisting of 
low CD163, low CCR2, high CX3CR1, and high CCR5 expression. (B) CXCL10 
(top row) and TNF-α (bottom row) production by monocytes in recently 
exposed individuals, a BCG-vaccinated donor, a TB patient, and a healthy 
control (HC) donor. (C) The percentage of total monocyte-derived CXCL10 
was positively correlated with the capacity to control mycobacterial out-
growth (n = 144). (D) The percentage of CD14bright cells producing CXCL10 did 
not correlate with mycobacterial growth control (n = 144). (E) The percent-
age of CD14dim cells producing CXCL10 correlated strongly with mycobacte-
rial growth control (n = 144). (F) Longitudinal follow-up of individuals from 
the supermarket contact investigation revealed increasing levels of growth 
control, which coincided with an increased percentage of CXCL10-produc-
ing CD14dim cells (line indicates mean of 8 samples). (G) Supernatants of 
4-day MGIA cocultures were tested for cytokine and chemokine production 
using a multiplex bead array. Shown are CXCL9 and CXCL10 production and 
CXCL9 production, expressed as picograms per milliliter, over the clinical 
groups. Groups were compared using the Kruskal-Wallis test. Controls,  
n = 43; BCG, n = 15; exposed, n = 79; LTBI, n = 44; TB, n = 21.
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tase PCR was performed for both splice variants on all samples 
that were available. Recently exposed individuals had a decreased 
ratio of CXCR3A over CXCR3B, as a result of both increased 
CXCR3B and reduced CXCR3A expression (Figure 5D). LTBI 
donors showed a similar trend toward a decreased ratio, but this 
did not reach statistical significance.
The CXCR3 receptor is most abundantly expressed on T cells, 
although it can also be expressed on monocytes, NK cells, and B 
cells. Since all MGIA data were obtained from total PBMCs, we 
wondered whether monocytes alone would be sufficient or wheth-
er the presence of T cells was required. First, data were compared 
for the percentage of central memory T cells (Tcm cells), since 
these cells typically express CXCR3 and may be responsible for 
the effector function (43). Since the presence of CXCL10-pro-
ducing CD14dim monocytes seems a first prerequisite for BCG 
control, groups were subdivided based on the percentage of 
CXCL10-positive cells as determined in Figure 4E, using a cutoff 
of 3%. Indeed, donors with good control of BCG outgrowth had 
tures revealed a similar pattern in the production of CXCL10 at day 
4 of the cultures, suggesting a feedback loop between chemokine 
production and receptor function (Figure 5C).
These opposing effects of the CXCR3 antagonist in donors 
that controlled versus those that did not control BCG outgrowth 
prompted us to assess expression of CXCR3 receptor alternative 
splice variants. Interestingly, although these splice variants differ 
only in the N-terminal part of this 7-transmembrane G protein–
coupled receptor, their intracellular effector coupling is differ-
ent (40, 41): CXCR3A is an immune-activating receptor and has 
the highest binding affinity for CXCL9, CXCL10, and CXCL11, 
whereas CXCR3B exerts a more inhibitory role and can also bind 
CXCL4 (42). The regulation of expression of each of the splice 
variants has not been resolved yet, but epigenetic modifications 
may play a role.
RNA samples were isolated from most PBMC samples 
(depending on cell yields) directly after thawing, without any 
stimulation, and stored. TaqMan quantitative reverse transcrip-
Figure 5. CXCR3 is key in determining mycobacterial outgrowth control. PBMCs were infected with live BCG 
and rotated for 4 days, and samples were incubated in MGIT tubes in the BACTEC machine. (A) A CXCR3 
receptor antagonist (NBI-74430) was added daily during the MGIA incubation period to inhibit activity of 
CXCL10; this reverted the capacity to control mycobacterial outgrowth. Data represent 11 donors with MGIA 
control run in 2 independent experiments; differences were assessed using the Wilcoxon matched-pairs 
signed-rank test. (B) Similar to A, addition of the CXCR3 receptor antagonist during the MGIA assay. Data 
represent 27 donors without MGIA control run in 3 independent experiments; differences were assessed 
using the Wilcoxon matched-pairs signed-rank test. (C) CXCL10 production was measured in supernatants 
of the MGIA assay at day 4 of coculture in samples with MGIA control or no MGIA control, in the absence or 
presence of NBI-74430, the CXCR3 antagonist. Data are expressed as median. (D) CXCR3 splice variants were 
determined by real-time quantitative reverse transcriptase PCR. ΔCt was calculated for both CXCR3A and 
CXCR3B using the in-well GAPDH control. Subsequently, the ratio of CXCR3A over CXCR3B was calculated 
and plotted. Data were compared using the Kruskal-Wallis test. Controls, n = 33; BCG, n = 16; exposed, n = 
63; LTBI, n = 26; TB, n = 16. (E) The percentage of Tcm cells was plotted for donors with a low frequency of 
CD14dim monocytes producing CXCL10 (<3%). Good, n = 11; intermediate, n = 20; no, n = 54. (F) The percentage 
of Tcm cells plotted for donors with a high frequency of CD14dim monocytes producing CXCL10 (>3%). Groups 
were compared using the Kruskal-Wallis test. Good, n = 22; intermediate, n = 22; no, n = 15. (G) MGIA assay 
with PBMCs and isolated fractions of monocytes with or without T cells. Cells were separated and combined 
in various ratios before infection with live BCG and 4-day coculture. Boxes and whiskers indicate donors that 
lack MGIA control (n = 8); lines indicate 3 individual donors with MGIA control.
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date these findings in additional, independent cohorts, preferably 
composed of recently exposed individuals. In addition, validation 
of these findings in human or nonhuman primate studies with 
novel vaccine candidates that induce protection, when available, 
would be extremely valuable. Detailed analysis of samples with 
strong control of bacterial outgrowth may contribute to the identi-
fication of novel correlates of protection.
Discussion
The present study reports that mycobacterial growth inhibition 
can be measured in humans using a refined and robust MGIA 
assay. Contrary to our expectation, improved mycobacterial 
growth control was not associated with (Th1) cytokine-produc-
ing (or polyfunctional) T cells, but rather was associated with the 
presence and activity of a nonclassical CD14dim monocyte sub-
set, but Tcm cells were required for growth control. Individuals 
with recent, but not remote, exposure to Mtb had the strongest 
capacity to control BCG outgrowth, suggesting that a temporary 
change in effector immunity occurred that mediated growth con-
trol. Indeed, nonclassical monocytes producing CXCL10 were 
found to be involved in BCG growth control through the CXCR3 
receptor. Expression of CXCR3 splice variants, with immune-acti-
vating or -inhibiting functions, was altered upon recent Mtb expo-
sure. Moreover, both CXCR3 ligands, CXCL9 and CXCL10, were 
also detected in samples of recently BCG-vaccinated individuals 
in which trained immunity was induced, suggesting that trained 
innate immunity was the mechanism behind control of BCG out-
growth in the MGIA following recent exposure to Mtb.
Mycobacterial growth control has been considered an import-
ant new readout of the capacity of the immune system to control 
BCG or Mtb, particularly because these assays are functional and 
do not require a specific a priori hypothesis regarding possible 
mechanisms involved. Since TB vaccines are designed to induce 
protective T cell immunity, the responsible immune effector cells 
in the MGIA assay have also been presumed to be T cell subsets. 
Recently, Smith et al. suggested an association between MGIA 
control capacity and the frequency of multifunctional CD4+ T 
cells, studying a small cohort of BCG-vaccinated infants (25). 
However, these data could not be replicated in our much larger 
cohort of individuals from different settings. In our view, the fre-
quencies of multifunctional T cells observed in both Smith’s and 
our study were extremely low; moreover, the negative control pop-
ulations that lack both multifunctional T cells and MGIA control 
skewed the trend lines strongly. Therefore, we conclude that mul-
tifunctional T cells are not associated with the capacity of human 
PBMCs to control BCG growth, at least in our larger cohorts, but 
likely also in others. Previous studies in mouse models of MGIA 
identified a role for IFN-γ in the control of BCG outgrowth (11). 
IFN-γ–deficient mice had reduced growth control, but these 
effects were most clear in conditions in which low numbers of 
splenocytes and relatively high BCG inocula were used (11).
Also in line with this observation is our finding that a consider-
able proportion of individuals who lack cellular immune respons-
es against Mtb, in TST and/or by IFN-γ production in QFN, con-
trolled BCG outgrowth quite well. Similarly, two-thirds of recently 
exposed individuals from the soccer club contact investigation did 
not convert their TST. All TST-negative individuals were tested 
higher frequencies of Tcm cells, suggesting that T cells and/or T 
cell–expressed CXCR3 is involved in control of BCG outgrowth 
(Figure 5, E and F). Second, we performed an additional series of 
MGIA experiments, in which we included not only total PBMCs, 
but also isolated monocytes and monocytes supplemented with 
purified autologous T cells. PBMCs from BCG controllers again 
inhibited outgrowth of BCG, which could be reversed with the 
CXCR3 antagonist as shown above (Figure 5G). However, isolated 
monocytes did not reduce the bacterial burden unless T cells were 
added (Figure 5G). Thus, both monocytes and T cells are required 
to control BCG outgrowth.
Trained immunity. Since we observed control of BCG out-
growth mostly in donors that were recently exposed to Mtb and 
since control of BCG outgrowth was associated with a particular 
subset of monocytes, we evaluated whether trained innate immu-
nity was responsible for the observed bacterial control. Trained 
immunity has previously been described in studies following 
BCG vaccination and in vitro restimulation with unrelated patho-
gen-derived pattern recognition receptor agonists (28, 29, 44). 
Cytokines that thus far have been reported as primary indicators 
of trained immunity are IL-1β, IL-6, and TNF-α. Samples from the 
MGIA assays of the above tested clinical groups were therefore 
analyzed for the production of these cytokines. Confirming our 
hypothesis, all 3 were found at increased levels in recently Mtb-ex-
posed individuals (Figure 6, A–C).
Next, in order to confirm that our above-defined CXCR3-bind-
ing chemokines are indeed associated with trained immunity, we 
assessed their concentrations in an independent cohort of recent-
ly BCG-vaccinated individuals from whom supernatants with 
classical trained immunity were obtained 4 weeks after vaccina-
tion. PBMCs isolated from volunteers vaccinated with placebo 
or BCG were restimulated for 24 hours in vitro with heat-killed 
Candida albicans, Staphylococcus aureus, Mtb, or lipopolysaccha-
ride. Although CXCL9 was detected in these BCG-trained sam-
ples (Figure 6D), CXCL10 was much more strongly upregulated 
(Figure 6E). CXCL11 was also found to be increased in the classi-
cal trained immunity samples (Figure 6F). These data show that 
CXCL9, CXCL10, and CXCL11 may be newly identified markers 
of trained immunity.
Additional cytokine and chemokine data were collected 
using a 40-plex bead array. We also analyzed these cytokines and 
chemokines for their induction both in classically trained sam-
ples and in our recently exposed individuals. Intriguingly, along 
with CXCL9, CXCL10, and CXCL11, also IL-4, CCL8 (MCP2), 
CCL11 (eotaxin), CCL17 (TARC), CCL19 (MIP3β), CCL23 (MIP3), 
CCL25 (TECK), CCL26 (MIP4α), CCL27 (C-TACK), and CXCL13 
(BLC) were identified as potential markers of trained immunity, 
deserving further research (Figure 6G).
Hence, we identified new markers of trained immunity and a 
series of candidate markers that deserve further investigation for 
their possible contribution to trained immunity effector mech-
anisms. The CXCR3 axis, involving both CXCL9 and CXCL10 
as ligands, has a functional role in mediating mycobacterial out-
growth control in the context of trained immunity. Monocyte fre-
quency, and in particular the CD14dim nonclassical monocyte pop-
ulation that produced CXCL10, may serve as surrogate markers 
for BCG outgrowth control. However, it remains important to vali-
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with their prevaccination sample (45). Monocyte signatures were 
most abundantly expressed and correlated with increased T cell 
responses to vaccination (45). These findings indicate that early 
activation of innate immune cells, with production of their respec-
tive cytokines, is critical for guiding the adaptive immune system.
Unexpectedly, nonclassical CD14dim monocytes were found 
to correlate strongly with the capacity to control BCG outgrowth. 
This cell population was abundantly present in individuals with 
recent TB exposure and strong MGIA growth reduction. Nonclas-
sical monocytes have been associated with a predominantly scav-
enging and sensing function within the immune system, in par-
ticular in the case of intracellular viral infections (46). These cells 
may also be involved in local tissue surveillance and have been 
linked to autoimmune diseases (46). Nonclassical monocytes 
are efficient recognizers of extracellular TLR ligands, but also of 
immune complexes. TLR triggering did not induce ROS or cyto-
kine production by CD14dim cells, but triggered specific production 
of TNF-α, IL-1β, and CCL3, e.g., by virus-induced TLR7/8 trig-
gering (47). TLR7/8 triggering also induced CXCL10 production 
by these cells, perhaps via a slightly different signaling pathway, 
since MYD88 was not essential for CXCL10 production, where-
as it is required for TNF-α and IL-1β production (47). In addition, 
besides their ability to release multiple cytokines, CD14dim cells are 
also highly motile, in agreement with their patrolling function, but 
are relatively weak phagocytes (47).
Intracellular analysis of several cytokines and chemokines 
revealed that the CD14dim monocyte population produced the 
CXCR3 ligand CXCL10, and CXCL10 production correlated 
strongly with BCG growth reduction. Indeed, CXCR3 receptor 
blockade using a chemical antagonist confirmed mechanistic 
involvement of the CXCR3 signaling pathway in BCG growth 
reduction. CXCR3 can bind not only CXCL10, but also CXCL9 
and CXCL11. These ligands were not present in our intracellular 
staining panel, but CXCL9, not CXCL11, was abundantly detected 
in supernatants. It remains to be seen whether a single or rather a 
combination of CXCR3 ligands is responsible for mediating BCG 
growth reduction. The effect of these chemokines may further 
depend on the balance in expression of splice variants of CXCR3, 
since in recently Mtb-exposed individuals a decreased ratio of 
CXCR3A over CXCR3B was observed. Although monocyte alter-
ations were most strongly associated with changes in control of 
BCG outgrowth, the presence of T cells was found to be indispens-
able to mediate ultimate BCG growth control by monocytes. In 
any event, we think this is the first molecular identification of a 
host effector molecule responsible for mycobacterial growth inhi-
bition, besides granulysin (48, 49).
Since our data suggested that the cellular ability to control 
mycobacterial growth was associated with recent exposure to 
Mtb, was transient, and was linked to the (nonclassical) mono-
cyte phenotype and (CXCR3 signaling–related) function, we 
hypothesized that this ability may have been acquired as a 
result of trained innate immunity by epigenetic changes in the 
myeloid cell lineage (28, 50). “Trained immunity” refers to 
the altered functional state of innate immune cells that per-
sists after elimination of the initial stimulus, and allows an 
increased response to restimulation of the cells through both 
the same and different pattern recognition receptors (50, 51). 
by TST a second time 6 weeks after initial TST reading, but many 
remained negative. When the capacity to control BCG outgrowth 
in the MGIA was compared in TST-positive (≥10 mm) versus 
TST-negative recently exposed individuals, no differences were 
observed; both subgroups controlled BCG outgrowth equally well. 
We therefore hypothesized that these individuals may efficiently 
have controlled bacterial growth through innate immunity, which 
could imply that induction of adaptive immunity was not needed 
and the TST therefore remained negative.
The ML ratio was very strongly associated with the capacity to 
control BCG outgrowth. Previous studies have also identified ML 
ratio as an important factor associated with the capacity to control 
in MGIA; however, a whole-blood version of the MGIA was used 
in that study, precluding a direct comparison with our data (24). 
Intriguingly, transcriptomic analysis of blood monocytes from 
those individuals identified IFN-γ among the top 5 upstream reg-
ulators, together with type I IFNs associated with early responses 
against intracellular infections (24). IFNs can have direct effects, 
but also augment effector responses through induction of several 
downstream inflammatory mediators such as IFN-inducible pro-
tein 10 (IP-10) or CXCL10. Thus, early activation of these tran-
scriptomic pathways in monocytes may also result in activation of 
CXCL10 and some of its family members. Gene expression stud-
ies in BCG-vaccinated mice already had identified CXCL9 as one 
of the most differentially expressed genes (12). Stimulation with 
BCG resulted in strong transcriptional upregulation of CXCL9 as 
well as CXCL10, in addition to TNF-α, IL-1β, and IL-6 (12), fitting 
perfectly with our trained immunity hypothesis. Also, in studies 
with the novel vaccine candidate MVA-Ag85A, CXCL10 was the 
top differentially transcribed gene at day 1 after vaccination both 
in South African infants and in UK adults (45). Vaccinated infants 
at day 28 also expressed more CXCL9 and CXCL10 compared 
Figure 6. CXCL10 production is a marker of trained immunity. Supernatants 
from the 4-day coculture with BCG were collected and cytokine/chemokine 
production determined using a multiplex bead array. In addition, samples 
were collected from in vivo, BCG-vaccinated individuals and stimulated ex 
vivo (restimulation with microbiological agents). Groups were compared 
using the Kruskal-Wallis test (A–C). (A) IL-1β production (as classical trained 
immunity marker) was assessed in 4-day culture supernatant. Controls,  
n = 43; BCG, n = 15; exposed, n = 79; LTBI, n = 40; TB, n = 20. (B) IL-6 production 
(as classical trained immunity marker) was assessed in 4-day culture super-
natant. Controls, n = 43; BCG, n = 16; exposed, n = 79; LTBI, n = 44; TB, n = 21. 
(C) TNF-α production (as classical trained immunity marker) was assessed 
in 4-day culture supernatant. Controls, n = 42; BCG, n = 16; exposed, n = 78; 
LTBI, n = 45; TB, n = 20. (D) CXCL9 (as new trained immunity marker) was 
measured in supernatants of ex vivo–stimulated PBMCs. Black bars indicate 
BCG-vaccinated donors (n = 10); open bars indicate placebo-vaccinated donors 
(n = 5). Results are expressed as fold change of 4 weeks post-vaccination 
over the prevaccination time point. CA, Candida albicans; SA, Staphylococcus 
aureus. (E) CXCL10 (as new trained immunity marker) was measured and 
expressed similarly as in D. (F) CXCL11 (as new trained immunity marker) was 
measured and expressed similarly as in D. (G) Summary of all cytokine and 
chemokine data collected in the multiplex bead array analysis using superna-
tants from individuals with trained immunity following BCG vaccination (top 
part; vaccinated donors only) and samples from individuals from TB infection 
cohorts from the current study (bottom parts). Dot sizes indicate the fold 
change compared with prevaccination for the trained cohort and fold change 
versus the control population in our clinical TB infection groups. Gray-shaded 
cytokines and chemokines are potentially associated with trained immunity.
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upon reinfection. Obviously, while this new hypothesis will need 
to be corroborated further in suitable animal models such a non-
human primate, collectively these observations point to an import-
ant role for innate and trained immunity in protective immunity 
against mycobacterial infections. These initial events are likely 
also important in guiding and steering the adaptive response, 
which is key to optimal protection as well. How exactly these dif-
ferent phenomena are causally, mechanistically, and temporally 
related remain topics for further study.
Recently, a mouse MGIA study was published that showed 
control of Mtb Erdman outgrowth in vaccinated mice (14). How-
ever, mice vaccinated only with the CAF01 adjuvant also showed 
such control, which was interpreted as an artifact. However, this 
observation could also fit with the induction of trained immuni-
ty. Moreover, the authors were unable to associate growth con-
trol with the number of cytokine-producing vaccine-specific T 
cells and found that there was no persistence of growth reduc-
tion at 29 weeks after vaccination (14). These data in fact fit well 
with the actual induction of temporary trained innate immunity 
as we report here.
Trained immunity has been described for monocytes. How-
ever, other circulating cells may also be instructed as a result of 
pathogen-induced training. MGIA control was associated not only 
with monocytic cell populations but also with B cells and CD4+ 
central memory cells. In contrast, numbers of total CD3+ T cells 
as well as CD4+ and CD8+ effector cells inversely correlated with 
mycobacterial growth control.CXCR3 expression is most abun-
dant on CD4 memory T cells, and T cells were required to medi-
ate BCG growth control, as isolated monocytes were unable to 
control BCG outgrowth. These data suggest an interplay between 
T cells and monocytes in the control of BCG outgrowth through 
the CXCL10/CXCR3 axis. It has previously been reported that 
the CXCR3+CCR6+ memory T cell population contained the vast 
majority of anti-Mtb reactive Th1 cells, and these rather unusual 
Th1 cells have been coined Th1* (43, 56). Thus not only innate cells 
but also CXCR3-expressing Mtb-specific T cells may be directed 
by CXCL10 produced by trained monocytes to mediate Mtb- 
specific immunity. An additional cell population in which trained 
immunity has been shown to be induced by BCG vaccination are 
NK cells (57). The importance of trained NK cells for protection 
has also been suggested by a recent clinical trial in which cor-
relates of protection after BCG vaccination were reported to be 
not CD8+ T cells, but IFN-γ–producing NK cells (58).
Although MGIA has been developed in principle as an in 
vitro measure of vaccine-induced protection, our data now show 
that growth control in the MGIA was the result of trained innate 
immunity, rather than of effector T cell induction. However, T 
cells appear to be involved in execution of growth control. To 
date, BCG is the only vaccine that induced partial protection 
against TB in humans, and it is well known to induce trained 
innate immunity. However, multiple new vaccine candidates are 
currently in clinical testing, and it is hard to speculate whether 
these vaccines induce protection in humans and whether these 
use (different) effector mechanisms. Therefore, we recommend 
future studies that analyze mechanisms of protection against 
mycobacteria to take into account not only effector T cell induc-
tion but also trained innate immunity.
In humans, we (M.G. Netea and colleagues) have shown that 
BCG vaccination induces trained immunity (28, 50). Indeed, 
cytokines previously associated with trained immunity such as 
TNF-α, IL-1β, and IL-6 were also increased in the current study 
in individuals with recent exposure to Mtb, suggesting trained 
immunity in these samples. Importantly, samples from previ-
ous trained immunity studies were shown in the current study 
to contain large amounts of CXCL10, and also CXCL9 and 
CXCL11, thus bridging these previous trained immunity studies 
now with our current TB cohort observations, and newly iden-
tifying CXCL9 and CXCL10 as markers of trained immunity. 
Future studies on the epigenetic alterations of these genes will 
be required to fully establish these chemokines as novel trained 
immunity markers.
Trained immunity–associated cytokines were detected in the 
majority of individuals with recent exposure to Mtb, but only in 
a limited number of individuals with more remote LTBI or TB 
disease. This suggests that Mtb infection–induced training of 
monocytic cell lineages is a temporary phenomenon during the 
first period after infection. This is in line with our earlier obser-
vation that BCG vaccination exerts strong trained immunity 
effects for several months, but these effects diminish 1 year after 
vaccination (29). It is difficult to estimate the duration of per-
sisting trained immunity after recent exposure, in particular in 
Mtb infection, since in many cases the exact timing of infection 
is unknown. However, the contact investigation in the supermar-
ket allowed identification of the presumed infectious period and 
included longitudinal follow-up (37). Somewhat to our surprise, 
most contacts from that outbreak maintained the capacity to con-
trol BCG in the MGIA during the 2 years of follow-up from initial 
exposure. The lifespan of circulating monocytes is estimated to 
be in the magnitude of days, implying that training must occur 
at the monocytic progenitor level to allow longer-lasting train-
ing effects. Mycobacteria have been found in human and mouse 
stem cells (52) in the bone marrow, and it is possible that this 
niche could be involved in training innate immune cells. Future 
studies in animals would be needed to demonstrate a causal link 
between functional reprogramming of myeloid cell progenitors 
and trained immunity in TB.
BCG-induced trained innate immunity may underlie some 
well-known observations, such as that infants vaccinated with BCG 
are protected from secondary infections against unrelated patho-
gens (53). Epidemiological studies suggested that these effects 
can last for several months until up to possibly multiple years (54). 
Circulating monocytes with trained immunity functional pheno-
types have been detected at 3 and 12 months following BCG vacci-
nation (29). Epidemiological evidence has furthermore indicated 
that prior LTBI strongly protects against development of active TB 
upon reinfection (27). Moreover, BCG vaccination has the highest 
efficacy in the absence of prior sensitization or preexisting infec-
tion (55). In analogy with these epidemiological findings, experi-
mental vaccination studies revealed that MGIA growth reduction 
is induced by priming BCG vaccination but not upon secondary 
BCG vaccination (9). The mechanisms behind this protective effi-
cacy in primary infection/vaccination have not been resolved, but 
may be explained by continuous innate immune training, which 
is capable of limiting unrelated as well as related bacterial growth 
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In addition, we obtained specific permission (protocol B16.002) 
from the ethical review board at Leiden University Medical Center to 
use archived samples remaining after completion of previous studies 
— in particular, contact investigations at a soccer club (original proto-
col 136/97) (34), in a supermarket (original protocol P05.053) (35–37), 
and among immigrants with a recent TB contact (original protocol 
P04.114) (38, 39).
Finally, BCG vaccination studies in healthy male volunteers were 
executed in Nijmegen, approved by the Arnhem-Nijmegen Medical 
Ethical Committee with protocol NL50160.092.24.
Experimental design. Archived PBMCs were thawed, rested, and 
counted. Cells were split for BCG-based MGIA as well as direct stim-
ulation with live BCG for flow cytometry including intracellular cyto-
kine staining. Remaining cells were dispensed in TRIzol reagents. 
Supernatants were collected after 4 days of coculture in the MGIA 
system. Upon analysis of MGIA data as well as flow cytometry data, 
cytokine and chemokine measurements were initiated, and functional 
experiments were designed.
Statistics. All data were analyzed assuming a non-Gaussian 
distribution, and therefore nonparametric testing was applied. All 
legends contain detailed information on the statistical tests applied 
and the number of individuals included for analysis. Generally, for 
comparison of groups, Kruskal-Wallis or Wilcoxon paired-rank tests 
were applied depending on the number of groups in the equation. 
For the analysis of longitudinal data, an ANOVA with Friedman test 
was applied. Correlations were based on linear regression model-
ing. All analyses were performed using GraphPad Prism version 
7.00 (GraphPad Software Inc.).
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Originally, trained immunity was demonstrated measur-
ing the production of IL-6, TNF-α, and IL-1β upon stimula-
tion. Here, we identify CXCL9 and CXCL10, and potentially 
CXCL11, as new markers of trained immunity. Moreover, our 
measurements of cytokines and chemokines in supernatants 
of recently exposed individuals as well as classical trained 
immunity samples revealed a number of additional candi-
date molecules induced during trained immunity: IL-4, CCL8 
(MCP2), CCL11 (eotaxin), CCL17 (TARC), CCL19 (MIP3β), 
CCL23 (MIP3), CCL25 (TECK), CCL26 (MIP4α), CCL27 
(C-TACK), and CXCL13 (BLC). A considerable number of these 
chemokines are associated with the macrophage inflammato-
ry response, supporting an association with trained immunity. 
However additional studies are required to demonstrate their 
functional role in trained immunity.
In conclusion, we have shown that MGIA control in human 
PBMCs is associated with recent Mtb infection. Control of BCG 
outgrowth was strongly linked to the presence of a nonclassical, 
CD14dim monocyte subset. The combination of the association 
with recent exposure, the temporary nature of growth reduction, 
and the presence of a particular monocyte subset led to the iden-
tification of trained innate immunity as the mechanism behind 
mycobacterial growth control. Indeed we were able to identify 
classical markers of trained innate immunity induced in myco-
bacterial control samples. In addition, we mechanistically link 
the CXCL10/CXCR3 axis as critical to BCG growth control as 
well as to trained immunity. Involvement of the CXCR3 axis may 
reflect the link between innate and adaptive cells involved in 
mycobacterial growth control. These studies have opened nov-
el avenues to assess protective immunity against a major human 
pathogen, and may redirect our thinking on vaccine-induced 
immunity and correlates of protection in TB.
Methods
An extended version of Methods is available as supplemental informa-
tion online.
Ethics and study samples. Human participation in this research 
was according to the US Department of Health and Human Ser-
vices and Good Clinical Practice guidelines. This included pro-
tocol approval by the Leiden University Medical Center Ethics 
Committee and written informed consent by all donors. Anony-
mous buffy coats from healthy blood bank donors were used only if 
donors had consented scientific use of blood products. Specifically, 
healthy control donor samples were in vitro PPD-negative healthy 
buffy coats obtained from Sanquin blood transfusion services, the 
Netherlands. The group of healthy donors was supplemented with 
healthy Dutch donors before BCG vaccination, after extensive 
testing of their mycobacterially naive status. These donors were 
subsequently BCG vaccinated and analyzed at 4, 8, and 12 weeks 
and 1 year after BCG vaccination; the BCG vaccination study was 
approved with protocol P12.087 (30). A longitudinal follow-up 
study of individuals with LTBI was also run at Leiden University 
Medical Center and approved under protocol P07.048 (31). In addi-
tion, a cohort with known long-term TB latency and age-matched 
uninfected controls were recruited in Norway after approval by the 
Regional Committees for Medical and Health Research Ethics in 
Norway (protocol P027/99) (32, 33).
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